Phase 1 Trial of STX-478 Shows Promise for PI3K-Mutated Solid Tumors with Reduced Toxicity
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 1/by MaxIn Vivo: CRISPR/Cas9 Gene Editing Shows Promise in Prostate Cancer Treatment
/0 Comments/in CRISPR, Preclinical Research/by MaxIn Vitro: Targeted Cancer Therapy with 4armPEG-DD: A Precision Approach for Prostate Cancer
/0 Comments/in Delivery, Preclinical Research/by MaxIn vivo: Menadione Sodium Bisulfite (vitamin K3) as a Pro-Oxidant Therapy for Prostate Cancer
/0 Comments/in Preclinical Research/by MaxPost-hoc of ARASENS for metastatic hormone sensitive prostate cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxDarolutamide Plus ADT and Docetaxel Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk in ARASENS Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxARX517 Achieves Key Safety and Efficacy Milestones in Phase 1/2 Trials for Metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025